4.21
-0.06 (-1.41%)
| Previous Close | 4.27 |
| Open | 4.12 |
| Volume | 1,690,737 |
| Avg. Volume (3M) | 3,280,670 |
| Market Cap | 1,121,401,344 |
| Price / Book | 8.33 |
| 52 Weeks Range | |
| Earnings Date | 16 Mar 2026 |
| Diluted EPS (TTM) | -0.880 |
| Total Debt/Equity (MRQ) | 43.67% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -206.18 M |
| Levered Free Cash Flow (TTM) | -118.45 M |
| Return on Assets (TTM) | -23.84% |
| Return on Equity (TTM) | -71.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Sana Biotechnology, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -1.13 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.46% |
| % Held by Institutions | 89.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Flagship Pioneering, Llc | 31 Dec 2025 | 25,001,856 |
| 52 Weeks Range | ||
| Median | 7.00 (66.27%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 06 Jan 2026 | 7.00 (66.27%) | Buy | 4.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Jan 2026 | Announcement | Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 08 Dec 2025 | Announcement | Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |